Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | PREP | P48147 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631031 | 1.00 | GRIN2B (0.41) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| SCHEMBL192363 | 1.00 | GRIN2B (0.41) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| Hydrochloric Acid SCHEMBL17063978 | 0.98 | GRIN2B (0.41) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| SCHEMBL14956788 | 0.95 | GRIN2B (0.38) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| SCHEMBL705581 | 0.95 | GRIN2B (0.38) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| SCHEMBL14956785 | 0.95 | GRIN2B (0.38) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| SCHEMBL4249117 | 0.90 | USP2 (0.40) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| SCHEMBL6078246 | 0.90 | USP2 (0.40) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| SCHEMBL7227763 | 0.90 | USP2 (0.40) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK | |
| SCHEMBL15116613 | 0.87 | GRIN2B (0.41) | GRIN2BGRIN2CUSP2SMN1; SMN2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103702981-B | Process for producing optically active 2-methylproline derivative | KANEKA CORP. (JP) | 2015-11-25 | — | — | CN | claimed |
| EP-2735560-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-METHYLPROLINE DERIVATIVE | Kaneka Corporation (JP) | 2014-05-28 | — | — | EP | claimed |
| CN-103702981-A | Process for producing optically active 2-methylproline derivative | KANEKA CORP | 2014-04-02 | — | — | CN | claimed |
| EP-4743175-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-12577259-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4695236-A1 | SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4608509-A1 | NEW INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-09-03 | — | — | EP | disclosed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| WO-2025106920-A1 | PARP PET IMAGING AGENTS AND METHODS OF USING THE SAME | YALE UNIVERSITY (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-113382750-B | CDCP1 targeted therapy | 贝斯以色列女执事医疗中心 | 2025-05-09 | — | — | CN | disclosed |
| EP-1001764-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999064395-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999026921-A1 | SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1998053814-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| US-5736518-A | Peptide compounds of (L) amino acids and ring molecules, and therapeutical applications thereof | POLIFARMA S.P.A. (IT) | 1998-04-07 | — | — | US | disclosed |
| EP-0503044-B1 | PEPTIDE COMPOUNDS OF LAEVOROTATORY AMINO ACIDS AND RING MOLECULES, AND THERAPEUTICAL APPLICATIONS THEREOF | POLIFARMA SPA (IT) | 1996-06-12 | — | — | EP | disclosed |
| US-5504071-A | HYPOTENSIVE AGENTS | POLIFARMA S.P.A. (IT) | 1996-04-02 | — | — | US | disclosed |
| EP-0503044-A1 | PEPTIDE COMPOUNDS OF LAEVOROTATORY AMINO ACIDS AND RING MOLECULES, AND THERAPEUTICAL APPLICATIONS THEREOF. | POLIFARMA SPA (IT) | 1992-09-16 | — | — | EP | disclosed |
| WO-1992006108-A1 | PEPTIDE COMPOUNDS OF LAEVOROTATORY AMINO ACIDS AND RING MOLECULES, AND THERAPEUTICAL APPLICATIONS THEREOF | POLIFARMA S.P.A. (IT) | 1992-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577259-B2 | PCSK9 antagonist compounds | PCSK9, LDLR, PCSK6 | GRIN2B 1861/4885GRIN2C 984/4885USP2 3226/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | GRIN2B 3931/4885GRIN2C 4690/4885USP2 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.